Paratz, Elizabeth D. http://orcid.org/0000-0002-2122-9889
Scheffer, Ingrid E.
Semsarian, Christopher
Funding for this research was provided by:
University of Melbourne
Article History
Accepted: 31 March 2023
First Online: 21 April 2023
Compliance with Ethical Standards
:
: Elizabeth D. Paratz reports PhD Scholarships from NHMRC and the National Heart Foundation, and a Senior Research Fellowship from Melbourne University. She is also the Deputy Medical Director for the East Timor Hearts Fund. Ingrid E. Scheffer has served on scientific advisory boards for BioMarin, Chiesi, Eisai, Encoded Therapeutics, Garvan Institute of Medical Research, GlaxoSmithKline, Knopp Biosciences, Nutricia, Rogcon, Takeda Pharmaceuticals, UCB, and Xenon Pharmaceuticals; has received speaker honoraria from GlaxoSmithKline, UCB, BioMarin, Biocodex, Chiesi, Liva Nova, Nutricia, Zuellig Pharma, and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, Biomarin, Encoded Therapeutics, National Research Foundation, Singapore and Eisai; has served as an investigator for Anavex Life Sciences, Cerecin Inc., Cerevel Therapeutics, Eisai, Encoded Therapeutics, EpiMinder Inc, Epygenyx, ES-Therapeutics, GW Pharmaceuticals, Marinus Pharmaceuticals, Neurocrine BioSciences, Ovid Therapeutics, Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceuticals, Zogenix and Zynerba Pharmaceuticals; and has consulted for Care Beyond Diagnosis, Epilepsy Consortium, Atheneum Partners, Ovid Therapeutics, UCB, Zynerba Pharmaceuticals, BioMarin, Encoded Therapeutics, and Biohaven Pharmaceuticals; and is a Non-Executive Director of Bellberry Ltd. and a Director of the Australian Academy of Health and Medical Sciences and the Australian Council of Learned Academies Limited. She may accrue future revenue on pending patent WO61/010176 (filed: 2008): Therapeutic Compound; has a patent for <i>SCN1A</i> testing held by Bionomics Inc. and licensed to various diagnostic companies; has a patent molecular diagnostic/theranostic target for benign familial infantile epilepsy (BFIE) [PRRT2] 2011904493 and 2012900190 and PCT/AU2012/001321 (TECH ID:2012–009). They also report Australian National Health and Medical Research Council (NHMRC) Centre for Research Excellence Grant (GNT2006841) 2020–2024; NHMRC Synergy Grant (GNT2010562) 2022–2026; NHMRC Senior Investigator Fellowship (GNT1172897) 2021–2025; and Einstein Visiting Fellowship (2022–25). Christopher Semsarian reports grants from the National Heart Foundation.
: This article does not contain any studies with human or animal subjects performed by any of the authors.